0001209191-20-028268.txt : 20200511 0001209191-20-028268.hdr.sgml : 20200511 20200511162507 ACCESSION NUMBER: 0001209191-20-028268 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200507 FILED AS OF DATE: 20200511 DATE AS OF CHANGE: 20200511 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Primiano Christopher Brett CENTRAL INDEX KEY: 0001603510 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 20865191 MAIL ADDRESS: STREET 1: C/O KARYOPHARM THERAPEUTICS INC. STREET 2: 85 WELLS AVENUE, SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-658-0600 MAIL ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-07 0 0001503802 Karyopharm Therapeutics Inc. KPTI 0001603510 Primiano Christopher Brett C/O KARYOPHARM THERAPEUTICS INC. 85 WELLS AVENUE NEWTON MA 02459 0 1 0 0 EVP, CBO, GC & Secretary Common Stock 2020-05-07 4 S 0 6714 19.6168 D 4649 D Common Stock 2020-05-07 4 M 0 2946 6.54 A 7595 D Common Stock 2020-05-07 4 S 0 2946 20.00 D 4649 D Stock Option (right to buy) 6.54 2020-05-07 4 M 0 2946 0.00 D 2026-01-14 Common Stock 2946 10054 D These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.37 to $20.00, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Includes 996 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan. This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. /s/ Christopher B. Primiano 2020-05-11